CORE--BIOSAFETY LEVEL-3 FACILITY

核心——生物安全三级设施

• 批准号: 6583723
• 负责人: ELIZABETH RICH
• 金额: $ 19.62万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-04-01 至 2003-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6583723
• 关键词: AIDS; Mycobacterium tuberculosis; biohazard control; biomedical facility; human immunodeficiency virus; microorganism culture; occupational health /safety; simian immunodeficiency virus

The primary mission of the Biosafety Core Support Facility (Core E) is to provide a fully manage, equipped and safe working environment where infectious pathogens, including (but not restricted to) HIV and Mycobacterium tuberculosis (M.tb) can be studied by investigators at CWRU and affiliated institutions, including the Cleveland Clinic Foundation. Dedicated BL-3 (approximately 1200 square foot) and BL-2 laboratories (approximately 150 square foot) including the Cleveland Clinic Foundation. Dedicated BL-3 (approximately 1200 square foot) and BL-2 laboratories (approximately 150 square foot), located immediately adjacent to each other on the 10th floor of the Biomedical Research Building in the Division of Infectious Diseases, are Available for Culture of HIV. The Core Support Facility provides state-of-the-art services to multiple CFAR investigators, permitting the culture and detection of both HIV and M.tb, thereby enhancing their research efforts. In addition to these services, Core personnel have assumed the responsibility of (a) familiarizing all BL-3 users in good laboratory practices and (b), pediatric retraining of all users to insure compliance with laboratory regulations. In addition to the Core Director (E.A. Rich), a 3-member Biosafety Committee (Drs. E.A. Rich, M.M. Lederman and Dr. S.F.J. Le Grice) meets on a periodic basis to supervise overall operational procedures. Since culture of an experimentation with biohazardous pathogens is a key element of AIDS research, this Facility constitutes an essential component of the CFAR. Key projects supported by Biosafety-3 Core Facility include: A human model of protective immunity (AI35207, J.J. Ellner); AIDS Clinical Trials Unit (AI25879, M.M. Lederman); Interaction of M.tb and HIV in the lung (HL51636, Z. Toosi); Expression of TB in the lung (HL-51630, E.A. Rich); Natural history of lymphocytic alveolitis in HIV disease (HL-53247, E.A. Rich); AIDS vaccine development-laboratory training (T2-00011, C. Whalen).

生物安全核心支持设施（核心E）的主要任务是 提供一个完全管理，设备齐全和安全的工作环境 感染性病原体，包括（但不限于）艾滋病毒和 CWRU的研究人员可以研究结核分枝杆菌（M.TB） 和附属机构，包括克利夫兰诊所基金会。 专用BL-3（约1200平方英尺）和BL-2实验室 （约150平方英尺），包括克利夫兰诊所基金会。 专用BL-3（约1200平方英尺）和BL-2实验室 （大约150平方英尺），位于每个附近 其他位于生物医学研究大楼10楼的 传染病分裂可用于艾滋病毒培养。这 核心支持设施为多个CFAR提供最先进的服务 研究人员允许培养和检测HIV和M.TB， 从而增强他们的研究工作。除了这些服务， 核心人员承担了（a）熟悉所有人的责任 BL-3用户进行良好的实验室实践和（b），儿科再培训 所有用户都确保遵守实验室法规。此外 核心董事（E.A. Rich）是一个由三人组成的生物安全委员会（E.A.博士） Rich，M.M。 Lederman和S.F.J.博士le grice）定期开会 监督整体操作程序。由于一种文化 生化病原体实验是艾滋病的关键要素 研究，该设施构成了CFAR的重要组成部分。 BioSafety-3支持的关键项目包括：人类模型 保护性免疫（AI35207，J.J。Ellner）；艾滋病临床试验单元 （AI25879，M.M. Lederman）；肺中M.TB和HIV的相互作用 （HL51636，Z. Toosi）; TB在肺中的表达（HL-51630，E.A。Rich）； HIV疾病中淋巴细胞肺泡炎的自然史（HL-53247，E.A。 富有的）; AIDS疫苗开发实验室培训（T2-00011，C。Whalen）。